retatrutide phase 3 trial results 3: TRIUMPH Program 2026 π¨ HOT OFF THE PRESS:
Description
Participants The study included over 1.2 million T2DM patients who were prescribed anti-diabetic medications, including 181,795 prescribed GLP-1RAs between April 2013 and April 2019
10.1507/endocrj.K08E-091 255
Common Examples Ozempic (semaglutide) Wegovy (higher-dose semaglutide) Mounjaro (tirzepatide) Initially used for type 2 diabetes, these meds now dominate the weight loss world
With 338 participants tracked across multiple dose groups, the data offers reliable insight into what new users can realistically expect
doi: 10.1016/j.jnutbio.2020.108377
Research is ongoing to understand the full potential of side effects and implications of taking GLP-1 RAs in these particular populations
